Home Cart Sign in  
Chemical Structure| 1260251-31-7 Chemical Structure| 1260251-31-7

Structure of Birinapant
CAS No.: 1260251-31-7

Chemical Structure| 1260251-31-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Birinapant (TL32711) is a bivalent Smac mimetic and a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in cells, resulting in the formation of a RIPK1 complex, caspase-8 activation, and induction of tumor cell death. It targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.

Synonyms: TL32711

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Birinapant

CAS No. :1260251-31-7
Formula : C42H56F2N8O6
M.W : 806.94
SMILES Code : FC1=CC2=C(C=C1)C(C[C@H]3N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C3)=C(C(N4)=C(C[C@H]5N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C5)C6=C4C=C(F)C=C6)N2
Synonyms :
TL32711
MDL No. :MFCD25976869
InChI Key :PKWRMUKBEYJEIX-DXXQBUJASA-N
Pubchem ID :49836020

Safety of Birinapant

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • cIAP

    cIAP1, Kd:<1 nM

  • XIAP

    XIAP, Kd:45 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
IMR-90 2 μM 24 h To identify genetic modifiers that enhance senescent cell death PMC10597643
TNBC PDX tumor cells 1 μM 24 or 48 h To evaluate the killing effect of Birinapant on TNBC PDX tumor cells, results showed that TNBC PDX tumor cells were sensitive to Birinapant PMC7492458
MDA-MB-231 cells 1 μM 24 h To evaluate the killing effect of Birinapant on MDA-MB-231 cells, results showed that MDA-MB-231 cells were sensitive to Birinapant PMC7492458
MDA-MB-468 cells 1 μM 24 h To evaluate the killing effect of Birinapant on MDA-MB-468 cells, results showed that MDA-MB-468 cells were sensitive to Birinapant PMC7492458
IMR-90 normal human lung fibroblasts 2 μM 24 h Screened for genetic modifiers of cell death, identified 14 hits passing 10% FDR threshold PMC10597643
PANC-1 cells 100 nM 0, 6, 24, 48, 72 h To investigate the effects of Birinapant in combination with gemcitabine on pancreatic cancer cells, the results showed synergistic effects involving cell cycle regulation and apoptosis signaling pathways. PMC5827530
MDA-MB-468 4 μM 48 h Birinapant significantly enhanced the immunotoxin-mediated killing of MDA-MB-468 cells, reducing the IC50 by 10-fold to 100-fold. PMC10659127
A431 4 μM 48 h Birinapant only modestly enhanced the immunotoxin-mediated killing of A431 cells, reducing the IC50 by only 5-fold. PMC10659127
HT-29 cells 1 µM 4 h Beclin 1-depleted HT-29 cells were more sensitive to TNF α-induced necroptosis PMC7560833
Molm-13 cells 0.05 µM 10 h Beclin 1-depleted Molm-13 cells were more sensitive to Smac mimetic and caspase inhibitor-induced necroptosis PMC7560833
NALM6 leukemia cells 50 nM 16 to 30 h To evaluate the effect of Birinapant and TNF combination on inducing extrinsic apoptosis in NALM6 leukemia cells, observing activation of caspase-8 and -9, and cleavage of effector caspase-3, -7, and -6. PMC6669006
Jurkat leukemia cells 50 nM To evaluate the effect of Birinapant and TNF combination on inducing extrinsic apoptosis in Jurkat leukemia cells, finding that cells lacking caspase-3 and -7 were resistant to ABT263 but remained sensitive to Birinapant and TNF-induced apoptosis. PMC6669006
B16F10 cells 1, 5, 10, 20 μM 48 h To test the effect of Birinapant on MHC-I and PD-L1 expression, results showed that Birinapant specifically upregulated MHC-I with minimal effect on PD-L1. PMC8543117
CT26 cells 1, 5, 10, 20 μM 48 h To test the effect of Birinapant on MHC-I and PD-L1 expression, results showed that Birinapant specifically upregulated MHC-I with minimal effect on PD-L1. PMC8543117

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CT-2A brain tumour model Intraperitoneal injection 30 mg/kg Not specified Birinapant in combination with anti-PD-1 antibody significantly extended the survival of mice bearing intracranial CT-2A tumours. PMC5330852
Mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 15 mg/kg 5 days To evaluate the effect of the ABT-199 and birinapant combination in clearing senescent cells in vivo PMC10597643
Mice TNBC PDX models Intraperitoneal injection 30 mg/kg Three times per week for seven weeks To evaluate the in vivo efficacy of Birinapant in TNBC PDX models, results showed that Birinapant significantly attenuated the growth of TNBC PDX models PMC7492458
Mice Bleomycin-induced pulmonary fibrosis model Intraperitoneal injection 15 mg/kg Once daily for 5 days Evaluated the effect of ABT-199 and birinapant combination therapy on senescent cell markers in a pulmonary fibrosis model, showing significant reduction in p16INK4a, Il6, Col1a2, and SA-βgal expression PMC10597643
Nude mice MDA-MB-468 and A431 tumor xenograft models Intraperitoneal injection 30 mg/kg Once daily for 22 days Combination therapy with birinapant and immunotoxin significantly inhibited the growth of MDA-MB-468 tumors, with complete regression in four out of five mice and 100% overall survival. PMC10659127
BALB/c nude mice Molm-13 cell xenograft model Intraperitoneal injection 2 mg/kg Every two days for two weeks Beclin 1-depleted Molm-13 cells were more sensitive to birinapant and emricasan-induced necroptosis, leading to significant reduction in tumor growth PMC7560833
Mice B16F10 melanoma model Intraperitoneal injection 600 μg/mouse Every 3 days for a total of 3 times To test the effect of Birinapant in combination with ICB treatment, results showed that Birinapant alone reduced tumor growth, and further reduced tumor progression when combined with ICB. PMC8543117

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01486784 Acute Myelogenous Leukemia PHASE1|PHASE2 TERMINATED 2025-04-15 Abramson Cancer Center of the ... More >>University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT01188499 Cancer PHASE1|PHASE2 COMPLETED 2025-03-14 Holy Cross Hospital, Fort Laud... More >>erdale, Florida, 33308, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, 48201, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, 19104, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Mary Crowley Cancer Research Center, Dallas, Texas, 75201, United States|South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, 78229, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.24mL

0.25mL

0.12mL

6.20mL

1.24mL

0.62mL

12.39mL

2.48mL

1.24mL

References

 

Historical Records

Categories